Claims for Patent: 12,042,488

Summary for Patent: 12,042,488

Title:	Methods of treating Fabry patients having renal impairment
Abstract:	Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Inventor(s):	Jeff Castelli, Elfrida Benjamin
Assignee:	Amicus Therapeutics Inc
Application Number:	US18/326,274
Patent Claims:	1. An α-galactosidase A protein having a HEK amenable mutation selected from the group consisting of: G334E, N34D and p.V254del, wherein the protein is bound to migalastat. 2. The α-galactosidase A protein of claim 1, wherein the mutation is G334E. 3. The α-galactosidase A protein of claim 1, wherein the mutation is N34D. 4. The α-galactosidase A protein of claim 1, wherein the mutation is p.V254del. 5. The α-galactosidase A protein of claim 1, wherein the protein bound to migalastat has increased stability as compared to a naturally-occurring α-galactosidase A protein having the same mutation. 6. The α-galactosidase A protein of claim 5, wherein the mutation is G334E. 7. The α-galactosidase A protein of claim 5, wherein the mutation is N34D. 8. The α-galactosidase A protein of claim 5, wherein the mutation is p.V254del. 9. An α-galactosidase A protein having a HEK amenable mutation N215I, wherein the protein is bound to migalastat. 10. The α-galactosidase A protein of claim 9, wherein the protein bound to migalastat has increased stability as compared to a naturally-occurring α-galactosidase A protein having the same mutation.